- CFO Dr. Wolfgang Colberg to leave the company on September 30, 2013
- Ute Wolf appointed to succeed him effective October 1, 2013
On June 21, 2013 the Supervisory Board of Evonik Industries AG resolved on termination of the term of office of Dr. Wolfgang Colberg (53) as Chief Financial Officer and a member of the Executive Board by mutual agreement, effective September 30, 2013. Further, the Supervisory Board appointed Ms. Ute Wolf (45) to the Executive Board as the new Chief Financial Officer of Evonik Industries AG effective October 1, 2013.
Werner Müller, Chairman of Evonik's Supervisory Board, stressed: "Mr. Colberg is leaving the company in best mutual agreement. Evonik has much to thank him for. Through his prudent approach, he played a key role in ensuring that the Group emerged strengthened from the financial crisis of 2008/2009. Other lasting contributions include his role in aligning the company to specialty chemicals and the successful preparation and realization of Evonik's stock exchange listing. On behalf of the Supervisory Board, I would like to thank Mr. Colberg most sincerely for that." Müller also commented: "Ms. Wolf is a highly qualified successor who has extensive experience of the capital markets thanks to her previous positions at three large listed corporations. I am certain that as our Chief Financial Officer she will play her part in shaping Evonik's future with enormous competence."
Klaus Engel, Chairman of the Evonik's Executive Board: "In Wolfgang Colberg we are losing a valued member of the Executive Board with whom we have always worked well. We are very pleased that his place will be taken by Ms. Wolf, an experienced manager from within the company."
Dr. Colberg has been CFO of Evonik since April 1, 2009. Ms. Wolf has been head of Evonik's Finance Division since January 1, 2006. She has a degree in mathematics and previously held a range of positions at Metro AG, Düsseldorf, Telekom AG, Bonn, and Deutsche Bank AG, Frankfurt.
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.6 billion and an operating profit (adjusted EBITDA) of about €2.6 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.